



Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to \$20.3 billion, and approximately 5 billion in Q1 2015. For more information, visit www.tevapharm.com.

Operating Income⁽¹⁾ and Cash Flow




Stock Chart




Net Revenues

(USD m)




Net Income (non GAAP¹)

(USD m)




Earnings Per Share (non GAAP)⁽¹⁾

(USD)



Dividends Per Share

(USD)



(1) See non GAAP reconciliation in our report for the (first quarter of 2015)

Q1 2015 Business Highlights

Generics:



- Revenue 2.6 billion, up 9% over Q1 2014
- Profit** up 950 bps over Q1 2014
- Successful Launch of Generic Nexium
- International Growth Markets – Double digit growth in local currency terms
- EU – Strong performance in Germany, UK and Italy. Record profitability levels
- OTC revenues up 20% in local currency terms

Specialty:

- Copaxone 40mg conversion rate at ~67%
- FDA approval of ProAir RespiClick
- Positive results for TEV-48125 in Phase IIb meeting primary and secondary endpoints for both chronic and episodic indications
- Reinforcement of CNS Leadership with Auspex Acquisition


Revenues by Markets and Segments

Q1 - 2015



Profit** by Segment

Q1 - 2015



* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices

** Profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

Teva Specialty pipeline - pending Auspex deal

Phase 1	Phase 2	Phase 3	Registration
TV-46763 (abuse deterrent) Pain	Laquinimod Multiple sclerosis (progressive forms)	Laquinimod Multiple sclerosis (relapsing remitting)	CEP-33237 ER Hydrocodone (abuse det.) US - Pain
TV-46139 (abuse deterrent) Pain	Laquinimod Huntington's disease	Fluticasone Propionate MDPI Asthma	Copaxone® 40mg 3w ROW Multiple sclerosis
Fluticasone Salmeterol Spiromax EU Asthma, COPD	Pridopidine Huntington's disease	Fluticasone Salmeterol MDPI Asthma	Copaxone® 20mg per Day Japan Multiple sclerosis
Reslizumab SC Asthma	TV-45070 Topical Osteoarthritis pain	QVAR® (BAI) US Asthma	Reslizumab IV Asthma
Fluticasone Salmeterol (MDI) EU Asthma, COPD	TV-45070 Topical Neuropathic pain	CEP-41750 (mesenchymal precursor cell) Chronic heart failure	Bendamustine Rapid Infusion* CLL, NHL
TEV-46017 (tidal inhaler) COPD	TEV-48125 (anti CGRP) Chronic and episodic migraine	SD-809 Tardive dyskinesia	
TEV-48108 (tidal inhaler) COPD	CEP-41750 (mesenchymal precursor cell) Acute myocardial infarction	SD-809 HD (Mid-2015 NDA filing)	
TEV-90110 HIV	Albutropin Growth hormone deficiency		
TEV-90112 HIV			
SD-809 Tourette syndrome			
SD-560 Idiopathic pulmonary fibrosis/ other fibrotic conditions			

- Auspex – pending deal completion
- CNS & Pain
- Respiratory
- Other

* Filed by Eagle Pharmaceutical, commercialized by Teva
 Note: Pipeline correct as of April 15, 2015. Phase 1 includes also projects designated for IND filing